Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xeris Pharmaceuticals Inc (NQ: XERS )

3.230 +0.010 (+0.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xeris Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Xeris Pharmaceuticals Provides Announcement Under the Irish Takeover Rules for Relevant Securities in Issue
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Executive Changes as Part of Its Strategy to Position the Company for Long-Term Commercial Success
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharma, Tetris Ink Commercialization Pact For Ogluo In Europe
Xeris Pharmaceuticals Inc (NASDAQ: XERS) has entered into an exclusive agreement with Tetris Pharma Limited to commercialize Ogluo in the European... 
Via Benzinga
Xeris Pharmaceuticals Enters Into an Exclusive License and Supply Agreement with Tetris Pharma Limited to Commercialize Ogluo® in Europe
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Get Ready for a XERS Stock Squeeze! Why One Analyst Thinks Xeris Could Be the Next AMC
XERS stock could very well be the next stock to get the short squeeze treatment, even without a r/WallStreetBets co-sign. 
Via InvestorPlace
55 Biggest Movers From Yesterday
Gainers DLocal Limited (NASDAQ: DLO) shares jumped 54.2% to close at $32.39 on Thursday. DLocal raised around $92.6 million from the sale of 4.4 million shares in its IPO. GTT... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Kindred Biosciences (NASDAQ:KIN) shares increased by 24.08% to $6.75 during Thursday's regular session. Kindred Biosciences's stock is trading at a volume... 
Via Benzinga
INVESTIGATION ALERT: Halper Sadeh LLP Investigates KSU, INSW, LMNX, XERS; Shareholders are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / May 27, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Kansas City Southern (NYSE:KSU) concerning... 
From Halper Sadeh LLP
Via AccessWire
Topics Fraud
Exposures Legal
Xeris Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Xeris Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XERS
From Halper Sadeh LLP
Via Business Wire
Mid-Afternoon Market Update: Dow Jumps 250 Points; Scopus BioPharma Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 0.75% to 34,462.98 while the NASDAQ rose 1.64% to 13,691.64. The S&P also rose, gaining 1.25% to 4,207.76. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Day Market Update: Crude Oil Rises 2.5%; NGM Biopharmaceuticals Shares Plunge
Midway through trading Monday, the Dow traded up 0.58% to 34,405.22 while the NASDAQ rose 1.43% to 13,663.92. The S&P also rose, gaining 1.04% to 4,199.05. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Mid-Morning Market Update: Markets Open Higher; Xeris Pharmaceuticals To Acquire Strongbridge Biopharma
Following the market opening Monday, the Dow traded up 0.50% to 34,378.59 while the NASDAQ rose 1.18% to 13,629.81. The S&P also rose, gaining 0.83% to 4,190.35. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Strongbridge Shares Shoot Higher After Xeris' Buyout Deal At $267M
Xeris Pharmaceuticals Inc (NASDAQ: XERS) has agreed to acquire Strongbridge Biopharma plc (NASDAQ: SBBP) for stock and contingent value rights (CVRs),... 
Via Benzinga
Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals: Q1 Earnings Insights
Shares of Xeris Pharmaceuticals (NASDAQ:XERS) rose 1.8% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 66.29%... 
Via Benzinga
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals to Webcast Upcoming Presentations
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million. •... 
Via Benzinga
Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
From Xeris Pharmaceuticals, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank
From Xeris Pharmaceuticals, Inc.
Via Business Wire
NASDAQ:XERS Shareholder Notice: Investigation over Potential Wrongdoing at Xeris Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 05/05/2021 -- Certain directors of Xeris Pharmaceuticals, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
From Xeris Pharmaceuticals, Inc.
Via Business Wire
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
With a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors?
A new, easier-to-administer treatment for severe hypoglycemia has observers and investors wondering where its creators will go next. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.